was achieved in 4 patients. No surgery-related mortality or signifi cant morbidity was reported. Adjuvant radiotherapy was delivered in 15 patients, and 30 patients received defi nitive radiotherapy. Conclusion: In the present study, the combination of paclitaxel, carboplatin and gemcitabine has been a safe and active regimen in poorprognosis stage IIIA N2 bulky NSCLC.
Introduction
Lung cancer is the leading cause of death worldwide [1] . Non-small cell lung cancer (NSCLC) is locally advanced stage III in one third of patients at diagnosis. Single modality therapy, with either surgery or radiotherapy alone, is curative for only a small minority of patients who present stage III. After initial therapy, a majority of patients suffers disease recurrence. Relapses are local in one third and distant in two third of patients. Therefore, one important stage of the therapeutic strategy is the use of chemotherapy in addition to local treatment in the management of locally advanced NSCLC. A number of phase II-III trials have investigated the use of induction chemo-therapy followed by surgical resection in patients with N2 disease [2] [3] [4] [5] [6] [7] [8] [9] . The data from these studies support the role of pre-operative chemotherapy in improving resectability and survival over surgery in stage IIIA N2.
The combination of paclitaxel and carboplatin is actually one of the common regimes used as induction chemotherapy for NSCLC. New triplet chemotherapy combinations are under investigation. The present study was designed to assess the effi cacy and safety profi le of paclitaxel, carboplatin and gemcitabine combination as induction chemotherapy for stage IIIA N2 bulky NSCLC. The primary endpoint of this study was objective radiological response. Secondary endpoints were survival, toxicity and safety of chemotherapy.
Patients and Methods

Patient Eligibility
Eligibility criteria were clinical stage IIIA NSCLC with pathologically documented N2 and locally unresectable disease. Mediastinal lymph nodes 1 2.0 cm in short-axis diameter at CT scan and measurable disease were required, as well as an age between 18 and 75 years and an Eastern Cooperative Oncology Group (ECOG) performance status ^ 2. Preserved haematologic and renal functions were also required. No previous cancer, arrhythmias or cardiac insuffi ciency 1 2 (New York Heart Association Scale) were admitted.
Further exclusion criteria were pregnancy and inadequate contraceptive precautions. All patients were required to provide written informed consent prior to initiation of treatment.
Study Design
This study was designed according to Simon's two-stage design [10] . The primary aim was to assess the effi cacy of paclitaxel, carboplatin and gemcitabine combination as induction treatment for patients with stage IIIA N2 bulky NSCLC. If the response rate was 6 50%, this induction chemotherapy was used in further patients. Baseline evaluation included complete history and physical examination, CT scan of brain, chest and upper abdomen, radionuclide bone scan, fi bre-optic bronchoscopy with bronchoaspirate and/or brushing and/or bronchial biopsy, complete blood cell count and serum chemistry analysis. Transbronchial needle aspiration (TBNA) and/or mediastinoscopy was routinely performed. All pretreatment imaging procedures were performed within 4 weeks from study entry. Tumour response was assessed with CT scan after three cycles according to WHO criteria. TBNA or mediastinoscopy was repeated in patients with no progressive disease, since chest CT scan is not accurate enough to predict pathological response in mediastinal lymph nodes. Patients without pathologically documented residual mediastinal disease were eligible for surgery. On the contrary, patients with pathologically (mediastinoscopy/TBNA/ thoracotomy) documented disease in the mediastinal nodes received defi nitive radiotherapy. The combined modality therapy of this study (chemotherapy and surgery and/or radiotherapy) did not allow the formal 4-week confi rmation of response to chemotherapy. Positron emission tomography was permitted, but not routinely performed. All toxicities were coded according to the National Cancer Institute Bethesda Common Toxicity Criteria [11] . The overall survival was estimated using the Kaplan-Meier technique [12] .
Treatment
Patients received paclitaxel 175 mg/mq on day 1, the carboplatin AUC 5 on day 1 and gemcitabine 1,000 mg/mq on day 1 and 8, every 3 weeks for three cycles. Paclitaxel infusion preceded carboplatin. Gemcitabine was infused after carboplatin infusion on day 1. All patients were pre-medicated with dexamethasone 8 mg given as an intravenous injection, chlorpheniramine 10 mg as intra-muscular injection and ranitidine 50 mg, intravenously. A combination of HT 3 antagonist and dexamethasone was administered to day 3 to prevent nausea and vomiting.
Treatment was repeated every 3 weeks if the neutrophil count was above 1,500/ml and platelets 1 100,000/ml. For patients who experienced drug toxicity, the dose for subsequent cycles was modifi ed as outlined in table 1 . After one episode of grade 4 neutropenia or febrile neutropenia, prophylaxis with recombinant human granulocyte colony-stimulating factors was administered. After grade 3-4 non-haematological toxicity, excluding hair loss, therapy was delayed until recovery. The use of recombinant erythropoietin was left to the individual decision of the physician. Within cycles, doses of gemcitabine on day 8 were modifi ed as follows: no reduction for neutrophils 1 1,500/ml and platelets 1 100,000/ml; 25% dose reduction for neutrophils 1,000-1,500/ml and/or platelets 75,000-100,000/ml; no administration for neutrophils ! 1,000/ml and/or platelets ! 75,000/ml. Three cycles of chemotherapy were administered unless progressive disease or intolerable toxicity was registered.
Results
Effi cacy
A total of 52 patients were enrolled from December 1999 to February 2004 ( table 2 ). All patients were assessable for response and toxicity. The overall response rate was 70% in the interim analysis which was performed in May 2002 after the fi rst 20 enrolled patients. Of the 52 evaluable patients, 40 responded, showing an overall response rate of 77% (95% CI 52-90%). Complete remission (CR) was achieved in 4 patients. Partial remission (PR) was observed in 36 patients. Stable disease (SD) was observed in 5 patients and progressive disease (PD) in 7. Repeated mediastinoscopy or TBNA was required in 15 patients.
Twenty-two patients were considered eligible for radical surgery after induction chemotherapy. At the present time, 17 patients were submitted to surgery with confi rmed pathological downstaging. Five were excluded for biopsy-proven residual tumour in mediastinal nodes at thoracotomy. Lobectomy was performed in 15 cases, while pneumonectomy was only performed in 2 patients. Resections were considered complete in 15 patients. Four patients achieved pathological complete response (pCR). Patients who achieved a pCR were those having a major radiographic response. No surgery-related mortality was reported and no signifi cant morbidity was observed during the 30 post-operative days. At a median follow-up of 26 months, the median duration of survival was 22 months (95% CI 16.9-32.1 months). Fifteen patients received adjuvant radiotherapy. Defi nitive radiotherapy (65 Gy) was given to 30 patients (23 with PR, 5 with SD and 2 with locoregional PD) with persistent mediastinal disease after induction chemotherapy. For these patients, the overall response was 83% after sequential chemoradiotherapy and the median overall survival was 20 months (95% CI 15.9-31.1 months). Among the 15 completely resected patients, 3 had disease recurrence 9-12 months after surgery.
Toxicity
The highest toxicity was a haematological one, with neutropenia as the major side effect. Only 2 patients had febrile neutropenia. Other less frequent high-grade toxicities included nausea-emesis, neuropathy, muscle pain, asthenia, diarrhoea and liver toxicity ( 
Discussion
Combined modality therapy involving a combination of chemotherapy and local treatment has improved outcomes for patients with stage III NSCLC: a 5-year survival of 25 and 15% in stages IIIA and IIIB can be expected. Stage IIIA, including tumours with ipsilateral mediastinal node involvement (T1-3N2), represents the most controversial subset of lung cancer patients because of the heterogeneity in clinical presentation, treatment and prognosis.
Despite a negative pre-operative staging including CT scan, positron emission tomography and mediastinoscopy, mediastinal lymph node metastases after thoracotomy (incidental N2) were found in some patients. Nodal disease was found at the fi nal pathological examination of surgical specimen or intra-operatively as an unexpected fi nding with frozen section pathologic examination of mediastinal nodes. However, a majority of patients with stage IIIA have enlarged ( 1 1 cm in short-axis diameter) N2 nodes at CT scan. In this setting, mediastinoscopy was generally performed, since approximately 40% of moderately enlarged nodes are benign. To optimize the chance for cure, patients with pre-operatively documented N2 and potentially resectable disease should receive induction chemotherapy followed by surgery. Theoretical advantages of induction chemotherapy include decreasing tumour size to allow more ready resection and decreased micrometastases and surgical seeding. In stage IIIA, preoperative phase II chemotherapy studies have shown improved outcome compared with historical controls. These studies showed a response rate of 64-77%, with 15-74% of complete resections and 0-18% treatment-related deaths. These results have been validated by three small randomized phase III studies [5] [6] [7] which, however, can be criticized on several points: no pathological staging of mediastinal nodes, inclusion of patients with inhomogeneous prognosis (T3 N0-1, bulky N2 or stage IIIB) and small samples. Furthermore, these results were not confi rmed by other studies [13] [14] [15] [16] and overall survival was not reported in two studies [13, 14] . No signifi cant survival benefi t for induction chemotherapy was achieved in two studies [15, 16] . At last, treatment-related mortality is high in some trials. However, for many patients with bulky N2 disease, the role of surgery is questionable.
These patients may be suitable for combined modality treatment with chemotherapy and radiotherapy, as several trials of induction chemotherapy followed by radiotherapy and of chemotherapy delivered concomitantly with radiotherapy have shown improved survival over defi nitive radiotherapy alone. Furthermore, three metaanalyses of trials comparing radiotherapy alone with cisplatin-based chemoradiation for locoregional disease have confi rmed the survival benefi t of combined modality therapy [17] [18] [19] . There have been trials of cisplatinbased sequential chemoradiation which have shown an advantage over combined modality therapy in patients with unresectable locoregional disease. In the fi rst trial of Dillman et al. [20] addressing this issue, the objective tumour response rate was improved with chemoradiation as compared with radiotherapy alone (56 vs. 43%). Additionally, a survival advantage over combination therapy was detected (5-year overall survival 13 vs. 6%). A trial by the Radiation Therapy Oncology Group [21] and a trial from France [22] also showed a survival benefi t of the use of sequential chemoradiotherapy.
These patients may be suitable for sequential radiotherapy as the disease is considered unresectable. Therapeutic strategy is complicated by the lack of a clear definition of what constitutes 'bulky N2' and/or 'unresectable' disease. The defi nition of 'resectable', 'marginally resectable' or 'unresectable' is not clear as it is subjective and highly dependent on the experience and expertise of the thoracic surgeon, as is the defi nition of bulky N2 disease. In this present study, bulky N2 disease is defi ned as involving mediastinal nodes 1 2 cm in short-axis diameter in CT scan.
Furthermore, since clinical restaging after induction chemotherapy with chest CT scans and/or positron emission tomography is not accurate to predict pathological response in mediastinal lymph nodes, repeated mediastinoscopy or TBNA was required in some patients. Patients with pathologically documented residual mediastinal disease were excluded from surgery and received defi nitive radiotherapy. Patients without mediastinal disease were submitted to surgery. In this present phase II study, the combination of paclitaxel, carboplatin and gemcitabine showed promising anti-tumoral activity and was well tolerated in combined modality therapy of stage IIIA N2 bulky NSCLC, with cytological or histological confi rmation of lymph node involvement. Objective response was achieved in 40/52 patients. Mediastinoscopy or TBNA was repeated after induction chemotherapy in some patients. After induction chemotherapy, 22 patients were considered eligible for radical surgery. Patients with pathologically documented residual mediastinal tumour were excluded for surgery. Seventeen patients were subjected to radical surgery with confi rmed pathological downstaging. Resections were considered complete in 15 patients. pCR was observed in 4 patients. No surgery-related mortality or signifi cant morbidity was observed. The use of induction chemotherapy appeared safe and did not increase surgical complications. At a median follow-up of 26 months, the median overall survival was 22 months. Thirty patients with persistent mediastinal disease after induction chemotherapy received defi nitive radiotherapy. For these patients (23 with RP, 5 with SD and 2 with locoregional PD after induction chemotherapy), the overall response rate was 83% after sequential chemoradiotherapy and the median overall survival was 20 months. These results are encouraging if compared with a number of trials using different platinum-based chemotherapy regimes followed by resection in stage IIIA.
In the largest published phase II trial, 136 patients with stage IIIA, with bulky or multilevel clinical N2, received two to three cycles of cisplatin-mitomycin and vinblastin or vindesine combination chemotherapy before exploratory surgery [2] . Seventy-seven of these patients responded to neo-adjuvant chemotherapy, 72% were surgically explored and 84% of them underwent complete resection of tumour tissue. pCR was achieved in 19% of the patients. The median survival of all patients was 19 months. In completely resected patients, median survival was 27 months. Survival was impressive ( 1 50% at 5 years) in patients who achieved complete response to the induction chemotherapy. This highlights the importance of a pCR for long-term survival. However, in trials employing the combination of cisplatin, vinca-alkaloid and mitomycin, a mortality of 18% was reported [3] . Indeed, triple combination with 'older drugs' as induction chemotherapy may be associated with high treatment-related mortality. Newer generation chemotherapeutic agents are being incorporated into combined modality therapy for locally advanced NSCLC. The EORTC 09858 phase II study reported that carboplatin and taxol are an active induction regimen in biopsy-proven stage IIIA N2 bulky NSCLC [23] . Of the 52 eligible patients, 33 responded (1 CR and 32 PR) at an overall response rate of 64%. Median overall survival was 20.5 months. Grade 3-4 neutropenia was reported in 63% of patients. A total of 35 patients was randomized to additional surgery or radiotherapy according to the protocol. From the 15 patients randomized in the surgery arm, 12 received surgery. Resection was considered complete in 2 of them. One patient died 5 days after surgery with pulmonary hypertension. Furthermore, a phase II trial of combined modality therapy, with carboplatin and paclitaxel concurrent with radiotherapy, yielded an overall response rate of 55% in 38 valuable patients [24] . Triple combination with carboplatin and new drugs gemcitabine and paclitaxel may be superior to paclitaxel and carboplatin alone as induction chemotherapy. Data from several studies [25] [26] [27] have evaluated the addition of gemcitabine to paclitaxel plus carboplatin in advanced NSCLC. The response rates ranged from 21 to 61%. Only a mild increase in trombocythopenia was observed as compared with paclitaxel and carboplatin alone. Preliminary results of randomized trials in advanced NSCLC indicated an advantage for drug combination paclitaxel, carboplatin and gemcitabine as compared with paclitaxel and carboplatin alone [23, 28, 29] . In the present study, the combination of paclitaxel, carboplatin and gemcitabine is an active regimen in bulky N2 disease. Forty of the 52 eligible patients responded. Seventeen patients were submitted to surgery. Resection was considered complete in 15 of them. Additionally, 4 patients achieved pCR. The studies conducted in N2 disease have pointed towards improved survival for those patients able to undergo a complete resection and for patients who achieved pCR after induction chemotherapy. In conclusion, this regimen is safe, and no treatment-related mortality or signifi cant morbidity was reported. These results are encouraging. Phase III studies are currently underway to verify the role of induction chemotherapy and to assess the best chemotherapy to be used.
